Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions

Autor: Dennis A. Hesselink, Dirk Jan A.R. Moes, Florian Lemaitre, Mariadelfina Molinaro, Raman Venkataramanan, Stein Bergan, Loralie J. Langman, Laure Elens
Přispěvatelé: Université Catholique de Louvain = Catholic University of Louvain (UCL), Mayo Clinic [Rochester], Erasmus University Medical Center [Rotterdam] (Erasmus MC), Oslo University Hospital [Oslo], Leiden University Medical Center (LUMC), Universiteit Leiden, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Epidémiologie, Evaluation et Politiques de Santé (EA 4069), Université Paris Descartes - Paris 5 (UPD5), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Jonchère, Laurent, Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), UCL - SSS/LDRI - Louvain Drug Research Institute, UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, Internal Medicine
Rok vydání: 2020
Předmět:
drug-drug interactions
medicine.medical_treatment
[SDV]Life Sciences [q-bio]
remdesivir
Review Article
030226 pharmacology & pharmacy
chloroquine
chemistry.chemical_compound
0302 clinical medicine
Pharmacology (medical)
Drug Interactions
tacrolimus
media_common
experimental treatments
Alanine
medicine.diagnostic_test
Immunosuppression
calcineurin inhibitors
3. Good health
[SDV] Life Sciences [q-bio]
immunocompromised
Systematic review
sirolimus
covid-19
Drug Monitoring
mammalian target of rapamycin inhibitors
Coronavirus Infections
Immunosuppressive Agents
mycophenolic acid
Drug
medicine.medical_specialty
hydroxychloroquine
media_common.quotation_subject
therapeutic drug monitoring
Pneumonia
Viral
protease inhibitors
Antibodies
Monoclonal
Humanized
Antiviral Agents
03 medical and health sciences
Betacoronavirus
tocilizumab
Therapeutic index
Tocilizumab
SDG 3 - Good Health and Well-being
medicine
Humans
Intensive care medicine
Glucocorticoids
Pandemics
Pharmacology
business.industry
SARS-CoV-2
COVID-19
transplant patients
everolimus
Tacrolimus
Adenosine Monophosphate
Transplant Recipients
cyclosporin
Transplantation
lopinavir
chemistry
Therapeutic drug monitoring
recommendations
business
Zdroj: Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, 2020, 42 (3), pp.360-368. ⟨10.1097/FTD.0000000000000761⟩
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2020, 42 (3), pp.360-368. ⟨10.1097/FTD.0000000000000761⟩
Therapeutic Drug Monitoring, 42(3), 360-368. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring, Vol. 42, no. 3, p. 360-368 (2020)
Therapeutic Drug Monitoring, 42(3), 360-368. Lippincott Williams & Wilkins
ISSN: 1536-3694
0163-4356
DOI: 10.1097/FTD.0000000000000761⟩
Popis: International audience; Background - COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs (ISDs). It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals. Methods - This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of ISDs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature. Results - Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining ISD concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight. Conclusions - With this article, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with ISDs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.
Databáze: OpenAIRE
Externí odkaz: